R negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

Meilani Syampurnawati\textsuperscript{a,b}, Eiji Tatsumi\textsuperscript{a}, Bambang Ardianto\textsuperscript{a}, Mariko Takenokuchi\textsuperscript{c}, Yuji Nakamachi\textsuperscript{c}, Seiji Kawano\textsuperscript{c}, Shun-ichi Kumagai\textsuperscript{c}, Katsuyasu Saigo\textsuperscript{d}, Toshimitsu Matsui\textsuperscript{f}, Takayuki Takahashi\textsuperscript{f}, Ken-ichi Nagai\textsuperscript{g}, Gunadi\textsuperscript{h}, Hisahide Nishio\textsuperscript{h}, Hiroki Yabe\textsuperscript{i}, Shin-ichi Kondo\textsuperscript{j} and Yoshitake Hayashi\textsuperscript{a}

\textsuperscript{a}International Center for Medical Research and Treatment (ICMRT), Graduate School of Medicine, Kobe University, Chuo-Ku, Kobe 650-0017, Japan

\textsuperscript{b}Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine University of Indonesia, Ciptomangunkusumo Hospital, Jakarta, Indonesia

\textsuperscript{c}Department of Laboratory Medicine, Graduate School of Medicine, Kobe University, Japan

\textsuperscript{d}Division of Blood Transfusion, School of Medicine Kobe University, Japan

\textsuperscript{e}Division of Hematology-Oncology, Kobe University Hospital, Japan

\textsuperscript{f}Department of Immunology and Hematology, Kobe Central City Hospital, Kobe, Japan

\textsuperscript{g}Institute of Biomedical Research and Innovation, Kobe, Japan

\textsuperscript{h}Department of Public Health and Genetic Epidemiology, Graduate School of Medicine, Kobe University, Japan

\textsuperscript{i}Department of Internal Medicine, Ako City Hospital, Ako, Japan

\textsuperscript{j}Department of Internal Medicine, Kakogawa City Hospital, Kakogawa, Japan

Received 11 June 2007;
revised 12 November 2007;
accepted 13 November 2007.
Available online 3 January 2008.

Abstract

Our previous observation of a higher incidence of FLT3-ITD in DR\textsuperscript{−} M1/M2 AML than in DR\textsuperscript{+} M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR\textsuperscript{−} AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2\%) of DR\textsuperscript{−} cases, but not in any of
28 DR⁺ cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.

**Keywords:** NPM1 mutation; FLT3 mutation; HLA-DR-negative AML

Diakses dari: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T98-4RH2SV8-2&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_searchStrId=1002951882&_rerunOrigin=scholar.google&_acct=C000050221&_version=1&_urlVersion=0&_userdid=10&md5=0ca3664bd91e55a1b1ffaa4f21874ec1